Cargando…
CHF6001 Inhibits NF-κB Activation and Neutrophilic Recruitment in LPS-Induced Lung Inflammation in Mice
Inhibitors of phosphodiesterase 4 (PDE4) are potent anti-inflammatory agents, inhibiting the production of inflammatory mediators through the elevation of intracellular cAMP concentrations. We studied the activity of a novel PDE4 inhibitor, CHF6001, both in vitro in human cells and in vivo, using bi...
Autores principales: | Stellari, Fabio F., Sala, Angelo, Ruscitti, Francesca, Buccellati, Carola, Allen, Andrew, Risé, Patrizia, Civelli, Maurizio, Villetti, Gino |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6863066/ https://www.ncbi.nlm.nih.gov/pubmed/31798449 http://dx.doi.org/10.3389/fphar.2019.01337 |
Ejemplares similares
-
Anti‐inflammatory effects of the novel inhaled phosphodiesterase type 4 inhibitor CHF6001 on virus‐inducible cytokines
por: Edwards, Michael R., et al.
Publicado: (2016) -
Monitoring inflammation and airway remodeling by fluorescence molecular tomography in a chronic asthma model
por: Stellari, Fabio, et al.
Publicado: (2015) -
Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD
por: Singh, Dave, et al.
Publicado: (2019) -
Azithromycin inhibits nuclear factor-κB activation during lung inflammation: an in vivo imaging study
por: Stellari, Fabio F, et al.
Publicado: (2014) -
Efficacy and safety of CHF6001, a novel inhaled PDE4 inhibitor in COPD: the PIONEER study
por: Singh, Dave, et al.
Publicado: (2020)